Guoxin Securities releases Marubi Biotech research report: operational fundamentals remain solid, awaiting profitability optimization

NightAirdropper · 2026-04-08T00:28:10+00:00

Guoxin Securities gives Marubi Biotech an "Outperform the Market" rating, citing increased online marketing and rising expense ratios leading to profit pressure. Risks include macroeconomic fluctuations and intensified industry competition. Meanwhile, Goldman Sachs believes the Federal Reserve is unlikely to cut interest rates this year.

NightAirdropper

2026-04-08 00:28:10

Abstract generation in progress

Each-day Economic News AI Express: On April 6, Guosen Securities released a research report saying it gives Marubi Bio (603983.SH, latest price: 24.36 yuan) an “Outperform the Market” rating. The main reasons for the rating include: 1) an increase in online spending and depreciation and amortization, putting pressure on profits in stages; 2) multiple factors leading the expense ratio to rise. Risk warning: risks in the macro environment, sales falling short of expectations, and intensifying industry competition.

Each-day Economic News Headline (nbdtoutiao) — Major U.S. data has been released. The Federal Reserve’s rate cuts this year are up in the air! Will it switch to rate hikes? Goldman Sachs provides four reasons: “The possibility is very small.”

(Reporter Wang Xiaobo)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before use. Any risk arising from actions taken based on this shall be borne by you.

Daily Economic News

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.